LA JOLLA PHARMACEUTICAL CO Form 8-K March 10, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 9, 2004

La Jolla Pharmaceutical Company

(Exact Name of Registrant as Specified in Charter)

Delaware 0-24274 33-0361285 (State or Other (Commission (IRS Employer

Jurisdiction

of Incorporation) File Number) Identification No.)

6455 Nancy Ridge Drive, San 92121

Diego, California

(Address of Principal Executive (Zip Code)

Offices)

Registrant s telephone number, including area code: (858) 452-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

EXHIBIT 99.2

Table of Contents

Item 5. Other Events and Required FD Disclosure.

On March 9, 2004, the Company issued a press release announcing that Steven Engle, the Company s Chief Executive Officer, would present at the SG Cowen 24th Annual Healthcare Conference on March 11, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On March 10, 2004, the Company issued a press release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits. The following exhibits are filed with this report on Form 8-K:

Exhibit Number	Description of Exhibit
99.1	Press Release announcing that the
	Company would present at the SG
	Cowen 24th Annual Healthcare
	Conference
99.2	Press Release announcing that Gail
	Sloan was promoted to Vice President
	of Finance, Controller and Secretary

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: March 10, 2004 By: /s/ Gail A. Sloan

Gail A. Sloan

Vice President of Finance and

Controller

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press Release announcing that the Company would present at the SG Cowen 24th Annual Healthcare
	Conference
99.2	Press Release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary